Compare Neurocrine Biosciences Inc (NBIX) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Petróleo Brasileiro SA — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while Petróleo Brasileiro SA trades at $20.98 (market cap $130.37B). The key difference: Petróleo Brasileiro SA is far larger — about 8.3× Neurocrine Biosciences Inc's market cap, and Petróleo Brasileiro SA pays a 8.03% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | PBR | |
|---|---|---|
Market Cap | $15.77B | $130.37B |
Sector | Health | Technology |
52-Week High | $185.50 | $22.03 |
52-Week Low | $123.10 | $11.54 |
Enterprise Value | $15.78B | $190.79B |
Dividend Yield | — | 8.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
PBR trades at $20.83, up 3.53% today, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a low P/E of 5.26, robust net income margin of 24.52%, and record Q2 2026 earnings beating estimates. Recent news highlights regulatory approvals for new drilling in Brazil and exploration in Ghana, signaling growth potential.
Outlook is positive given low valuation, high profitability, and expansion efforts, but risks include geopolitical factors and oil price volatility. Analyst consensus leans bullish with 50% buy ratings, though the stock faces headwinds from softer crude prices and execution risks in new projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
